文献速递儿童青少年精神心境障碍

妊娠期ADHD药物使用与流产风险

Attention-deficit hyperactivity disorder medication use in pregnancy and risk of miscarriage.
PubMed 文献 · Br J Psychiatry · 2025-11-07

妊娠期任何ADHD药物使用与流产风险升高相关(aOR 1.60,95%CI 1.41-1.83),最高剂量三分位组aOR达2.11(95%CI 1.71-2.60)。

要点

  • 妊娠期任何ADHD药物使用与流产风险升高相关(aOR 1.60,95%CI 1.41-1.83)。
  • 哌甲酯、赖右苯丙胺和阿托莫西汀均与流产风险升高相关。
  • 药物暴露剂量越高,流产风险越高,最高三分位组aOR 2.11(95%CI 1.71-2.60)。

核心结论

  • 妊娠期ADHD药物使用与流产风险升高相关,且风险随暴露剂量增加而升高。

主要发现

  • 任何ADHD药物使用与流产风险升高相关(aOR 1.60,95%CI 1.41-1.83)。
  • 哌甲酯(aOR 1.55,95%CI 1.35-1.79)、赖右苯丙胺(aOR 1.81,95%CI 1.06-3.10)和阿托莫西汀(aOR 2.34,95%CI 1.41-3.89)均与流产风险升高相关。
  • 按总限定日剂量三分位分组,流产风险随暴露水平升高而增加,最低三分位aOR 1.14(95%CI 0.91-1.42),最高三分位aOR 2.11(95%CI 1.71-2.60)。

关键数值与推荐

  • 流产定义为妊娠20周前的妊娠丢失。
  • ADHD药物暴露定义为任何使用(一次或以上配药处方),并按总限定日剂量三分位分类作为剂量代理。

临床怎么用

  • 对育龄期患ADHD女性,妊娠期使用ADHD药物需权衡流产风险与精神症状控制获益。
  • 临床决策时应考虑药物剂量与流产风险的剂量-反应关系。

局限性

  • 配药处方可能不能反映实际用药。
  • 需要进一步研究以明确这些关联并细化风险估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An increasing number of women of childbearing age are treated for attention-deficit hyperactivity disorder (ADHD). Limited evidence exists on risk of pregnancy loss associated with ADHD medication use in early pregnancy. AIMS: To assess whether ADHD medication use during pregnancy is associated with increased risk of miscarriage. METHOD: We conducted a nationwide, register-based, case-control study, using linked Norwegian data from Medical Birth Registry of Norway, Norwegian Patient Registry, Norwegian Control and Payment of Health Reimbursements Database and Norwegian Prescription Database. Among pregnant women with ADHD, those with miscarriage (n = 2993 cases) were matched with up to four live births (n = 10 305 controls) by maternal age and year of conception. ADHD medication exposure during pregnancy was defined as any use (one or more filled prescriptions) and categorised into tertiles of total defined daily doses (DDDs) as a proxy for dose. The main outcome was miscarriage (pregnancy loss before 20 weeks). Conditional logistic regression was used to estimate adjusted odds ratios (aORs) with 95% confidence intervals, adjusting for psychiatric comorbidities, psychotropic and teratogenic medications, and maternal age at conception. RESULTS: Of 13 298 pregnancies, 1389 (10.5%) were exposed to ADHD medications. Any ADHD medication use was associated with increased miscarriage risk (aOR 1.60, 95% CI 1.41-1.83). Methylphenidate (aOR 1.55, 95% CI 1.35-1.79), lisdexamfetamine (aOR 1.81, 95% CI 1.06-3.10) and atomoxetine (aOR 2.34, 95% CI 1.41-3.89) were associated with increased risks. Higher levels of medication exposure, categorised by DDD tertiles, were associated with increased odds of miscarriage, increasing from 1.14 (95% CI 0.91-1.42) for the lowest tertile to 2.11 (95% CI 1.71-2.60) for the highest. CONCLUSIONS: ADHD medication use during pregnancy is associated with increased miscarriage risk. However, filled prescriptions may not reflect actual use. Further research is needed to clarify these associations and refine risk estimates.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Srinivas C, Karlstad Ø, Stigum H, et al. Attention-deficit hyperactivity disorder medication use in pregnancy and risk of miscarriage. Br J Psychiatry. 2025. PMID: 41199455. doi:10.1192/bjp.2025.10467

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。